> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Playing Active Drug Pricing Role: Analysis
- URL: https://www.fdaweb.com/fda-playing-active-drug-pricing-role-analysis/
- Published: 2018-08-16T12:00:00.000Z
- Updated: 2026-09-15T00:26:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142127

Attorney **James Czaban** (Piper) says that although it has no direct authority to take action on drug pricing, “FDA has been an incredibly active player in the current administration’s efforts to address concerns about drug prices.” Writing in a Food and Drug Law Institute online [post](https://www.fdli.org/2018/08/update-for-fda-addressing-drug-pricing-is-a-matter-of-doing-its-job-better/?utm%5Fsource=t.co&utm%5Fmedium=referral), Czaban outlines agency actions under the general headings of a focus on competition and a focus on innovation.

“While I have suggested that some of these efforts are in essence just FDA trying to do its core job better and more efficiently,” Czaban writes, “that is by no means a criticism. Rather, many of the reforms being pursued have been debated for decades but are now being implemented with a fresh way of thinking that would be noteworthy even if there were no public controversy at all about drug pricing. And, by explicitly drawing connections between improving the operation of its core medical functions and impacting the affordability of drugs for American consumers and the healthcare system, FDA has not only advanced the drug pricing debate, but is building support for, and acceptance of, regulatory changes that in other contexts and at other times might never have gotten off the ground.”